Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (Nasdaq: GANX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Gain Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), and metabolic disorders. The company utilizes its proprietary Magellan™ computational platform to identify allosteric binding sites on proteins. Its lead product candidate, GT-02287, is in development for the treatment of Parkinson's disease (with and without GBA1 mutations).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20.2) million | $(20.4) million |
| Operating Expenses | $(18.7) million | $(20.4) million |
| Cash and Cash Equivalents (Year-End) | $20.8 million | $10.4 million |
| Cash Used in Operating Activities | $(18.5) million | $(18.9) million |
| Accumulated Deficit | $(101.4) million | $(81.2) million |
| Debt | $0.4 million | $0.4 million |
Note: The company has not generated any product revenue to date. Operating expenses consist primarily of research and development (R&D) and general and administrative (G&A) costs.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased slightly by $0.25 million to $20.2 million in 2025 compared to $20.4 million in 2024.
- Expense Optimization: Total operating expenses decreased by $1.6 million. R&D expenses declined by $0.6 million due to pipeline cost optimization, while G&A expenses decreased by $1.1 million driven by lower stock-based compensation and legal fees.
- Foreign Exchange Impact: The company incurred a net foreign exchange loss of $0.8 million in 2025, compared to a gain of $0.1 million in 2024, primarily due to the strengthening of the Swiss franc against the U.S. dollar.
- Liquidity Improvement: Cash and cash equivalents increased from $10.4 million to $20.8 million, bolstered by net proceeds of $28.4 million from financing activities, including a July 2025 public offering and sales under an At-The-Market (ATM) program.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- GT-02287 Phase 1b: Enrollment for the Phase 1b safety and tolerability study in Parkinson's patients was completed in September 2025. Part 1 (90 days) concluded in November 2025, with full analysis expected throughout 2026. Part 2 (9-month extension) is expected to complete in September 2026.
- Phase 2 Plans: The company plans to commence a Phase 2 study in the second half of 2026.
- Capital Runway: Management projects that current cash resources will fund operations into the first quarter of 2027. The company explicitly states there is substantial doubt about its ability to continue as a going concern beyond this period without additional financing.
Risks and Contingencies
- Going Concern: The company has a history of operating losses and expects to incur losses for the foreseeable future. It will need to raise additional capital, which may not be available on acceptable terms or at all.
- Legal Proceedings: On January 21, 2026, a former investor filed a complaint alleging breach of contract and fraud regarding warrant repricing, seeking damages in excess of $3.1 million. The company intends to vigorously defend the action.
- Intellectual Property: The company relies on an exclusive license from Minoryx Therapeutics, S.L. for its Magellan™ platform. Termination of this license would halt operations.
- Regulatory and Clinical Risks: Success in early clinical trials does not guarantee success in later stages. The company faces risks related to patient enrollment, regulatory approval, and the acceptance of data from foreign clinical trials by the FDA.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure additional financing before Q1 2027 to avoid operational curtailment.
- Phase 1b Data: Monitor the release of the full analysis of the Phase 1b Part 1 study data expected in 2026, which will be critical for advancing to Phase 2.
- Legal Exposure: Track the status of the lawsuit filed by Andrew Schwartzberg regarding warrant repricing and potential settlement costs.
- Financing Dilution: Assess the impact of future equity offerings (via ATM or public offerings) on shareholder dilution given the lack of revenue.
- Foreign Exchange Sensitivity: Monitor the impact of the Swiss franc and Euro exchange rates on operating expenses and pension obligations.